Ebook: Valuation in Life Sciences: A Practical Guide
- Tags: Finance /Banking, Computer Appl. in Life Sciences, Health Informatics, Pharmacy, Biotechnology, Management/Business for Professionals
- Year: 2008
- Publisher: Springer Berlin Heidelberg
- Language: English
- pdf
This book is the first complete guide to valuation in life sciences for industry professionals, investors, and academics. Boris Bogdan and Ralph Villiger introduce the characteristics of drug and medical device development, explain how to translate these into the valuation, and provide valuable industry data. After guiding the reader through the theory of valuation, including discounted cash-flow and real options, the authors demonstrate how to value projects, patents, licences, firms and stocks on real-life examples, even treating complex licence and company structures. Special emphasis is put on the practicability of the proposed methods by including many hands-on examples, without compromising on realistic results.
From the reviews:
Ralph Villiger and Boris Bogdan have written what is sure to become the industry standard reference for valuation of pharmaceutical and biotechnology projects and companies.
Dr. Martin Buckland, Chief Business Officer, Astex Therapeutics, Cambridge, UK
This book is the first complete guide to valuation in life sciences for industry professionals, investors, and academics. Boris Bogdan and Ralph Villiger introduce the characteristics of drug and medical device development, explain how to translate these into the valuation, and provide valuable industry data. After guiding the reader through the theory of valuation, including discounted cash-flow and real options, the authors demonstrate how to value projects, patents, licences, firms and stocks on real-life examples, even treating complex licence and company structures. Special emphasis is put on the practicability of the proposed methods by including many hands-on examples, without compromising on realistic results.
From the reviews:
Ralph Villiger and Boris Bogdan have written what is sure to become the industry standard reference for valuation of pharmaceutical and biotechnology projects and companies.
Dr. Martin Buckland, Chief Business Officer, Astex Therapeutics, Cambridge, UK
Content:
Front Matter....Pages i-xi
Introduction....Pages 1-9
Fundamentals in Life Sciences....Pages 11-26
Basics of Valuation....Pages 27-81
Valuation in Life Sciences....Pages 83-284
Exercises....Pages 285-309
Case Studies....Pages 311-325
Back Matter....Pages 327-334
This book is the first complete guide to valuation in life sciences for industry professionals, investors, and academics. Boris Bogdan and Ralph Villiger introduce the characteristics of drug and medical device development, explain how to translate these into the valuation, and provide valuable industry data. After guiding the reader through the theory of valuation, including discounted cash-flow and real options, the authors demonstrate how to value projects, patents, licences, firms and stocks on real-life examples, even treating complex licence and company structures. Special emphasis is put on the practicability of the proposed methods by including many hands-on examples, without compromising on realistic results.
From the reviews:
Ralph Villiger and Boris Bogdan have written what is sure to become the industry standard reference for valuation of pharmaceutical and biotechnology projects and companies.
Dr. Martin Buckland, Chief Business Officer, Astex Therapeutics, Cambridge, UK
Content:
Front Matter....Pages i-xi
Introduction....Pages 1-9
Fundamentals in Life Sciences....Pages 11-26
Basics of Valuation....Pages 27-81
Valuation in Life Sciences....Pages 83-284
Exercises....Pages 285-309
Case Studies....Pages 311-325
Back Matter....Pages 327-334
....